Neuroblastoma is a high-grade malignancy of childhood. It is chemo- and radio-sensitive but prone to relapse after initial remission.The aim of the current study was to study the results of the first- and second-line chemotherapy on the short-term response and long-term survival of children, and to further describe the side effects of treatment. Ninety-five children with advanced neuroblastoma were included in the study, divided into two groups according to the treatment strategy: 65 were treated by first-line chemotherapy alone, and 30 children who were not responding or relapsed after first-line chemotherapy were treated by second-line chemotherapy. External beam radiotherapy was given to bone and brain secondary cancers when detected. Staging workup was performed before, during and after management. Response was documented after surgery for the primary tumor. Median follow up was 32 months (range 24–60 months). Chemothe rapy was continued until toxicity or disease progression occurred, indicating interruption of chemotherapy. Patients received a maximum of 8 cycles. Toxicity was mainly myelo-suppression, with grade II-III severity in 60% of the firstline and 70% of the second-line chemotherapy patients. Median total actuarial survival was nearly 51 months for the first-line chemotherapy group and 30 months for the second-line line group, with a statistically significant difference between the two groups (P<0.01).

Neuroblastoma is a high-grade malignancy of childhood. It is chemo- and radio-sensitive but prone to relapse after initial remission. The aim of the current study was to study the results of the first- and second-line chemotherapy on the short-term response and long-term survival of children, and to further describe the side effects of treatment. Ninety-five children with advanced neuroblastoma were included in the study, divided into two groups according to the treatment strategy: 65 were treated by first-line chemotherapy alone, and 30 children who were not responding or relapsed after first-line chemotherapy were treated by second-line chemotherapy. External beam radiotherapy was given to bone and brain secondary cancers when detected. Staging workup was performed before, during and after management. Response was documented after surgery for the primary tumor. Median follow up was 32 months (range 24-60 months). Chemothe rapy was continued until toxicity or disease progression occurred, indicating interruption of chemotherapy. Patients received a maximum of 8 cycles. Toxicity was mainly myelo-suppression, with grade II-III severity in 60% of the firstline and 70% of the second-line chemotherapy patients. Median total actuarial survival was nearly 51 months for the first-line chemotherapy group and 30 months for the second-line line group, with a statistically significant difference between the two groups (P<0.01).

The aim of the current study is to focus on treatment response in patients with malignant pleural mesothelioma (mPm) treated with combination chemotherapy using cisplatin plus vinorelbine. Secondary endpoints included, toxicity, progression-free and overall survival. Patients and Methods: This prospective study included 26 patients with histologically proven unresectable mPm treated at Kasr El-Aini Center of Clinical Oncology and Nuclear medicine (NEmROCK) from march 2003 to August 2004. Patients were assigned to receive cisplatin 75mg/m 2 on day one and vinorelbine 25mg/m 2 on days one and 8 every three weeks. Results: All 26 patients had measurable disease and were assessed for response. Six patients had partial response (23%), 14 patients had stable disease (54%), and six patients had disease progression on therapy (23%). Toxicity was acceptable and no treatment-related deaths occurred. The median progression-free survival was 5.15 months and the median overall survival for was 10.3 months, with a 42.3% one-year survival. Conclusion: Cisplatin-vinorelbine combination is an effectve regimen for management of malignant pleural mesothelioma with a tolerable toxicity profile. Further studies with a larger number of patients is necessary.